SCHEMBL17582784

SCHEMBL17582784

CCOC(=O)c1ccc2nc(N)n(C3CCC3)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RPS6KB1 P23443 1/20 0.48
▸ ALDH1A1 P00352 4/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ PDE2A O00408 2/20 0.45
▸ GRK6 P43250 1/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ OPRM1 P35372 4/20 0.45
▸ OPRK1 P41145 4/20 0.45
▸ OGFRL1 Q5TC84 4/20 0.45
▸ OPRD1 P41143 3/20 0.45
▸ MAPT P10636 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ IDH1 O75874 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ PTGER4 P35408 1/20 0.43
▸ PDE10A Q9Y233 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ HPGD P15428 1/20 0.42
▸ LMNA P02545 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21310911 0.97 ALDH1A1 (0.52) RPS6KB1ALDH1A1MAPK1PDE2AGRK6
SCHEMBL21310910 0.91 GRK6 (0.46) RPS6KB1ALDH1A1MAPK1PDE2AGRK6
SCHEMBL2030741 0.88 L3MBTL1 (0.57) RPS6KB1ALDH1A1MAPK1PDE2AALOX15
SCHEMBL2031010 0.82 RPS6KB1 (0.49) RPS6KB1ALDH1A1PDE2AGRK6MAPT
SCHEMBL2031012 0.82 RPS6KB1 (0.49) RPS6KB1ALDH1A1PDE2AGRK6MAPT
SCHEMBL18779170 0.82 RORC (0.42) RPS6KB1ALDH1A1GRK6OPRM1OPRK1
SCHEMBL22382488 0.81 RPS6KB1 (0.51) RPS6KB1ALDH1A1PDE2AGRK6MAPT
SCHEMBL8286248 0.80 PDE2A (0.41) ALDH1A1MAPK1PDE2AALOX15MAPT
SCHEMBL30659089 0.79 IDH1 (0.47) RPS6KB1ALDH1A1MAPK1PDE2AOPRM1
SCHEMBL17582943 0.79 IDH1 (0.47) RPS6KB1ALDH1A1MAPK1PDE2AOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12351559-B2 Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators BIOHAVEN THERAPEUTICS LTD. (VG) 2025-07-08 — — US disclosed
US-20240300903-A1 BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD (US) 2024-09-12 — — US disclosed
EP-4289822-A2 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (US) 2023-12-13 — — EP disclosed
EP-4289822-A2 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (US) 2023-12-13 — — EP disclosed
EP-3572405-B9 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD (US) 2023-12-06 — — EP disclosed
US-11834418-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators BIOHAVEN THERAPEUTICS LTD. (VG) 2023-12-05 — — US disclosed
EP-3572405-B1 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2023-07-26 — — EP disclosed
EP-3572405-B1 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2023-07-26 — — EP disclosed
US-20210188782-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2021-06-24 — — US disclosed
US-20210188782-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2021-06-24 — — US disclosed
EP-3191457-A2 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS Knopp Biosciences LLC (US) 2017-07-19 — — EP disclosed
US-20170114022-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-04-27 — — US disclosed
US-20170114022-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-04-27 — — US disclosed
US-20170114022-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-04-27 — — US disclosed
US-9481653-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators KNOPP BIOSCIENCES LLC (US) 2016-11-01 — — US disclosed
US-9481653-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators KNOPP BIOSCIENCES LLC (US) 2016-11-01 — — US disclosed
US-9481653-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators KNOPP BIOSCIENCES LLC (US) 2016-11-01 — — US disclosed
WO-2016040952-A2 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2016-03-17 — — WO disclosed
US-20160075663-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-03-17 — — US disclosed
US-20160075663-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834418-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators KCNA7, KCNJ2, KCNK17 RPS6KB1 454/4885ALDH1A1 2106/4885MAPK1 1037/4885
US-20240300903-A1 BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS KCNA7, KCNK17, KCNK2 RPS6KB1 322/4885ALDH1A1 1492/4885MAPK1 825/4885
US-20170114022-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS KCNA7, KCNJ2, KCNK17 RPS6KB1 454/4885ALDH1A1 2106/4885MAPK1 1037/4885
US-20160075663-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS KCNA7, KCNJ2, KCNK17 RPS6KB1 454/4885ALDH1A1 2106/4885MAPK1 1037/4885
US-12351559-B2 Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators KCNA7, KCNJ2, KCNK17 RPS6KB1 527/4885ALDH1A1 2065/4885MAPK1 1036/4885
US-20210188782-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS KCNA7, KCNJ2, KCNK17 RPS6KB1 454/4885ALDH1A1 2106/4885MAPK1 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback